Pharnext

Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.

Pharnext SAS, a biopharmaceutical company, engages in the development of treatments for severe neurological diseases. The company specializes in drug repositioning. Its target pathologies include Charcot-Marie-Tooth disease; and diabetic and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral neuropathies. The company was founded in 2007 and is based in Paris, France.